A5011326091- Drug Transport and Resistance Mechanisms
- Pharmacological Effects and Toxicity Studies
- Drug Solubulity and Delivery Systems
- HIV/AIDS drug development and treatment
- Inflammasome and immune disorders
- IL-33, ST2, and ILC Pathways
- Pharmacogenetics and Drug Metabolism
- Atherosclerosis and Cardiovascular Diseases
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
Kyung Hee University
2021-2025
Seoul National University Hospital
2017
Progressive renal failure causes uremia-related immune dysfunction, which features a chronic inflammatory milieu. Given the central role of end-stage disease (ESRD)-related dysfunction in pathogenesis cardiovascular diseases (CVDs), much attention has been focused on how uremic toxins affect cellular immunity and mechanisms underlying atherosclerosis ESRD patients. Here, we investigated characteristics monocytes CD4+ T cells patients responses induced by indoxyl sulfate (IS), key toxin,...
Objectives: Ultrafiltration (UF) is widely accepted as a method for assessing the plasma protein binding (PPB) of drugs. However, it vulnerable to non-specific (NSB) device, which can result in inaccuracies. This study presents straightforward, high-throughput modified UF aimed at minimizing bias due NSB. Methods: The method, sequential UF, features addition 2 min pre-UF phase designed saturate NSB followed by main 20 procedure, compared conventional method. To evaluate feasibility this we...
Breast cancer resistance protein (BCRP) mediates pharmacokinetic drug interactions. This study evaluated the potential of quercetin to inhibit and induce BCRP in vitro vivo. The inhibition was investigated for its metabolites using BCRP/mBcrp1-overexpressing MDCKII cells by flow cytometry. induction LS174T quantitative PCR. expression rat small intestine, liver, kidney also measured after multiple administrations rats (50, 100, 250 mg/kg, seven days). vivo changes sulfasalazine following...
SCR430, a sorafenib derivative, is an investigational drug exhibiting anti-tumor action. This study aimed to have mechanistic understanding of SCR430’s time-dependent pharmacokinetics (TDPK) through ex vivo combined with in vitro–in extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modeling. A non-compartmental analysis was performed after intravenous SCR430 administration female Sprague-Dawley rats for control group (no treatment), vehicle (vehicle only, 14 days, PO),...